



For further information:
Investor Relations (Tel: +34 91 244 44 22)
Marta Campos Martínez mcampos@rovi.es

ROVI agrees to acquire assets of a manufacturing plant in San Sebastián de los Reyes

- **Through this operation, ROVI intends to strengthen its contract manufacturing business and ensure for the future the production capacity required to carry out its strategic international expansion of Bemiparin, and predictably, the commercialization of its potential new low molecular weight heparin, biosimilar of enoxaparin.**
- **The assets to be acquired by ROVI have an annual production capacity of 120 million syringes and 40 million vials.**
- **The acquisition is expected to be completed before the 1st July 2015.**

Madrid, 3rd June 2015 – Laboratorios Farmacéuticos Rovi, S.A. (ROVI) announces today that has reached an agreement with Crucell Spain, S.A. (Crucell) by which it will acquire assets of the manufacturing plant at San Sebastián de los Reyes, owned by Crucell, with the main objective to expand in the future the injectables production lines of ROVI's group (others than the ones being manufactured by Crucell). These production assets will remain inoperative for some time while ROVI carries out investments for necessary and significant adaptation and refurbishment. Through this operation, ROVI intends to strengthen its contract manufacturing business and ensure the production capacity required to carry out its future strategic plans of international expansion of Bemiparin and, predictably, marketing and development of its potential new low molecular weight heparin, biosimilar of enoxaparin. Until the to be acquired assets begin to operate and ROVI obtains relevant approvals, ROVI will perform the technical analysis required in order to adapt mentioned assets to ROVI's methodology and procedures.

The assets to be purchased by ROVI consist in three parcels in San Sebastián de los Reyes and a list of property assets, including: two production lines (one of them high speed) for the filling of syringes, one production line for the filling of vials, a high speed line for the inspection of syringes and other for syringe´s packaging.

By this agreement, ROVI will strengthen for the future its capacity to perform contract manufacturing operations as well as its international expansion strategy of Bemiparin and its potential new low molecular weight heparin, thus favouring company´s sustained growth in the long term. This agreement is in line with ROVI´s global strategy with its current manufacturing model to achieve greater effectiveness and allow its long term growth, while continue with its constant commitment of economic growth in Spain.

The agreement implies an investment by ROVI of approximately 4 million euros. The operation will be financed by available funds from the Company; therefore it has not being required seeking external financing. ROVI expects the acquisition to be completed before the 1st July 2015, when Crucell is in disposition to make the assets available to ROVI.

“This agreement promotes a sustained growth for ROVI, reinforcing two important engines of growth of the company, contract manufacturing and pharmaceutical specialties areas. Likewise, ROVI considers this agreement as an important element to maintain and contribute to economic and industrial growth in Spain, through the continuous development of innovative drugs that allow improving patients´ quality of life in Spain and in the rest of the world, said Juan López-Belmonte Encina, Chief Executive Officer of ROVI.

About ROVI

ROVI is a fully integrated Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI´s portfolio of 30 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, Bemiparin. ROVI´s research and development pipeline is focused

primarily on the expansion of applications, indications and alternative mechanisms of action for the heparin-derived products and other glycosaminoglycans and on the development of new controlled release mechanisms based on ISM® technology, with the aim of obtaining new pharmaceutical products that enable the regular administration of formulations which are administered daily in chronic and prolonged treatments. ROVI manufactures the active biological ingredient (Bemiparin) for its principal proprietary products and for injectable pharmaceutical products developed by its in-house research team, and utilizes its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. In addition, ROVI provides contract manufacturing and packaging services of solid oral pharmaceutical dosage forms, using the most enhanced technology, Roller Compaction. Additional information about ROVI is available on the company's website: www.rovi.es